Anne Joutel
From Wikipedia, the free encyclopedia
Anne Joutel | |
|---|---|
| Born | 20 March 1965 |
| Occupation(s) | Neurology, Genetics |
| Known for | Research into the genetic disease CADASIL |
| Awards | The Brain Prize |
Anne Joutel (born 1965) is a French neurologist and neuroscientist who is Research Director at the Institute of Psychiatry and Neurosciences of Paris. In 2019, together with three colleagues, she was awarded the Brain Prize, the largest prize awarded for brain research.[1]
Joutel was born on 20 March 1965. She became a Doctor of Medicine at the Paris Diderot University in France, with a specialisation in neurology. Between 1993 and 1998 she was in residence in university hospitals in Paris. She received a PhD in neuroscience, from the Pierre and Marie Curie University, now the Sorbonne University, in 1996.[1][2]
Career
Joutel was appointed as a research officer at the Institut national de la santé et de la recherche médicale (French National Institute of Health and Medical Research - Inserm) in 1998. From 2000 she conducted research at the Lariboisière Hospital Faculty of Medicine, where she became the Director. She is currently the Research Director at the Institute of Psychiatry and Neuroscience of Paris, Paris Descartes University, which is now part of the University of Paris. The Institute consists of a multi-disciplinary team of over 150 neuroscientists and others working on neurodevelopment and psychiatry; the neurovascular system; multiscale imaging; translational neuroscience, and molecular and cellular mechanisms in the ageing brain.[1][2][3]
Joutel studies the pathogenic mechanisms of small vessel diseases (SVD) of the brain. She has a long-standing interest in CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) and, as a PhD student, contributed to the identification of Notch 3, the genetic basis of CADASIL. She subsequently deciphered some of the key mechanisms driving cerebrovascular dysfunction. In partnership with the pharmaceutical company Lundbeck, she established the proof of concept of the therapeutic efficacy of passive immunization against Notch 3 in a pre-clinical CADASIL model. She now collaborates with Mark T. Nelson of the University of Vermont, USA as part of a Transatlantic Network of Excellence on the pathogenesis of cerebral SVD, funded by the Leducq Foundation. She also lectures at the University of Vermont.[1][2][3][4][5]